TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE

Brian H. Annex, George A. Beller

Research output: Contribution to journalReview article

Abstract

Atherosclerosis is the leading cause of morbidity and mortality in the Western world. Peripheral artery disease (PAD) has been less studied then coronary artery disease but is nearly as common. PAD impairs blood flow to the leg(s) and causes functional impairment, leg pain, and amputation. The last drug approved for PAD was in 1999. Blood flow to leg proceeds through one major artery and in PAD total occlusions in the course of that vessel are common. Thus, the extent of new blood vessel growth determines a patients' clinical course. Promoting the growth of new blood vessels (therapeutic angiogenesis) was a major goal of therapy. Results from studies using cytokine growth factors have shown disappointing results. Using clinical and preclinical studies, our laboratory has identified several novel therapeutic approaches. One, a modulator of innate immunity, will be reviewed as an approach that has the potential to create new therapies for PAD.

Original languageEnglish (US)
Pages (from-to)224-234
Number of pages11
JournalTransactions of the American Clinical and Climatological Association
Volume127
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Peripheral Arterial Disease
Leg
Blood Vessels
Therapeutics
Western World
Growth
Amputation
Innate Immunity
Coronary Artery Disease
Atherosclerosis
Intercellular Signaling Peptides and Proteins
Arteries
Cytokines
Morbidity
Pain
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE. / Annex, Brian H.; Beller, George A.

In: Transactions of the American Clinical and Climatological Association, Vol. 127, 01.01.2016, p. 224-234.

Research output: Contribution to journalReview article

@article{79a86f2d89924fc292d66c57d57bf9e8,
title = "TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE",
abstract = "Atherosclerosis is the leading cause of morbidity and mortality in the Western world. Peripheral artery disease (PAD) has been less studied then coronary artery disease but is nearly as common. PAD impairs blood flow to the leg(s) and causes functional impairment, leg pain, and amputation. The last drug approved for PAD was in 1999. Blood flow to leg proceeds through one major artery and in PAD total occlusions in the course of that vessel are common. Thus, the extent of new blood vessel growth determines a patients' clinical course. Promoting the growth of new blood vessels (therapeutic angiogenesis) was a major goal of therapy. Results from studies using cytokine growth factors have shown disappointing results. Using clinical and preclinical studies, our laboratory has identified several novel therapeutic approaches. One, a modulator of innate immunity, will be reviewed as an approach that has the potential to create new therapies for PAD.",
author = "Annex, {Brian H.} and Beller, {George A.}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "127",
pages = "224--234",
journal = "Transactions of the American Clinical and Climatological Association",
issn = "0065-7778",
publisher = "American Clinical And Climatological Association",

}

TY - JOUR

T1 - TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE

AU - Annex, Brian H.

AU - Beller, George A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Atherosclerosis is the leading cause of morbidity and mortality in the Western world. Peripheral artery disease (PAD) has been less studied then coronary artery disease but is nearly as common. PAD impairs blood flow to the leg(s) and causes functional impairment, leg pain, and amputation. The last drug approved for PAD was in 1999. Blood flow to leg proceeds through one major artery and in PAD total occlusions in the course of that vessel are common. Thus, the extent of new blood vessel growth determines a patients' clinical course. Promoting the growth of new blood vessels (therapeutic angiogenesis) was a major goal of therapy. Results from studies using cytokine growth factors have shown disappointing results. Using clinical and preclinical studies, our laboratory has identified several novel therapeutic approaches. One, a modulator of innate immunity, will be reviewed as an approach that has the potential to create new therapies for PAD.

AB - Atherosclerosis is the leading cause of morbidity and mortality in the Western world. Peripheral artery disease (PAD) has been less studied then coronary artery disease but is nearly as common. PAD impairs blood flow to the leg(s) and causes functional impairment, leg pain, and amputation. The last drug approved for PAD was in 1999. Blood flow to leg proceeds through one major artery and in PAD total occlusions in the course of that vessel are common. Thus, the extent of new blood vessel growth determines a patients' clinical course. Promoting the growth of new blood vessels (therapeutic angiogenesis) was a major goal of therapy. Results from studies using cytokine growth factors have shown disappointing results. Using clinical and preclinical studies, our laboratory has identified several novel therapeutic approaches. One, a modulator of innate immunity, will be reviewed as an approach that has the potential to create new therapies for PAD.

UR - http://www.scopus.com/inward/record.url?scp=85040833633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040833633&partnerID=8YFLogxK

M3 - Review article

C2 - 28066055

AN - SCOPUS:85040833633

VL - 127

SP - 224

EP - 234

JO - Transactions of the American Clinical and Climatological Association

JF - Transactions of the American Clinical and Climatological Association

SN - 0065-7778

ER -